Evaluation of the efficacy and safety of cross-linked hyaluronic acid
30 mg/ml for filling nasolabial folds

Dublin Core

Título

Evaluation of the efficacy and safety of cross-linked hyaluronic acid
30 mg/ml for filling nasolabial folds

Descripción

Introduction: the nasolabial folds (NLF) are a highly mobile facial region that undergoes multifactorial changes during aging. Cientific Hyaluronic Facial Implant 30® is a 30 mg/ml cross-linked hyaluronic acid (HRA) filler developed to optimize the results of this highly dynamic facial area.

Objectives: to evaluate the safety and efficacy of Cientific Hyaluronic Facial Implant 30® (CH30), composed of 30 mg/ml HRA, for the correction of moderate to severe NLF.

Materials and methods: a 12-month, prospective, multicenter clinical study that included 64 male and female patients between 30 and 75 years of age with moderate to severe NLF treated in both NLFs with CH30 to balance the asymmetry until optimal correction was achieved. Efficacy assessments by evaluators included analysis of NLF severity using the Wrinkle Severity Rating Scale (WSRS) and improvement using the Global Aesthetic Improvement Scale (GAIS). Safety was recorded throughout the study based on checks at each appointment and patient reporting of adverse events.

Results: no adverse events were observed during the 12-month follow-up. In 100% of cases, defect correction, duration, and satisfaction were rated by patients and physicians as “improved” to “very improved,” with a very slow decrease in effect observed at 12 months.

Conclusions: the use of AHR for the treatment of NLF is one of the most effective and safe options in current aesthetic medicine. Its ability to restore volume, smooth wrinkles, and improve skin quality make it a key tool for facial rejuvenation. The durability of the results, combined with its low complication rate, makes HRA widely recommended for patients seeking a natural and longlasting aesthetic improvement, making it one of the most popular interventions in modern aesthetic medicine.

Autor

Marcelo Robles: Plastic and Reconstructive Surgeon, Medical Director, Robles Clinic, City of Buenos Aires, Argentina. ORCIDO: https://orcid.org/0009-0003-5622-8514

Claudio Dachevsky: Plastic Surgeon, General Manager, Lipo Plastic Surgery Clinic, São Paulo, Brazil

Fuente

I. Russell-Goldman E, Murphy GF. The pathobiology of skin aging. New insights into an old dilemma. Am J Pathol 2020 Jul;190(7):1356-1369. doi: 10.1016/j. ajpath.2020.03.007.

II. Lupo M. Hyaluronic acid fillers in facial rejuvenation. Seminars in cutaneous medicine and surgery 2006; 25:122-6. doi: 10.1016/j.sder.2006.06.011.

III. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg 1998 Dec;24(12):1317-25. doi: 10.1111/ j.1524-4725.1998.tb00007.x.

IV. Braccini F, Fanian F, García P, et al Comparative clinical study for the efficacy and safety of two different hyaluronic acid-based fillers with Tri-Hyal versus Vycross technology. A long-term prospective
randomized clinical trial. J Cosmet Dermatol 2023. Feb;22(2):473-485. doi: 10.1111/jocd.15200.

V. Peña F. Factores relacionados a la durabilidad del ácido hialurónico reticulado. Rev Facultad de Medicina de la Universidad de lberoamérica 2023;2;13-21. doi 10.54376/rcmui.v2i2.148.

VI. Wongprasert P, Dreiss CA, Murray G. Evaluating hyaluronic acid dermal fillers. A critique of current characterization methods. Dermatol Ther 2022 Jun;35(6):e15453. doi: 10.1111/dth.15453.

VII. Sánchez-Carpintero D, Ruiz-Rodríguez R. Materiales de relleno: tipos, indicaciones y complicaciones. Actas Dermosifiliogr 2010;101(5):381-393.

VIII. Bukhari SNA, Roswandi NL, Waqas M, Habib H, Hussain F, et al. Hyaluronic acid, a promising skin rejuvenating biomedicine. A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 2018 Dec;120(Pt B):1682-1695. doi: 10.1016/j. ijbiomac.2018.09.188.

IX. Martínez-Carpio PA, Vega López PM. Materiales de relleno temporales en medicina estética: revisión de la literatura sobre la incidencia de efectos adversos y complicaciones. Medicina Estética 2019;59(2):14-19. doi: 10.48158/MedicinaEstetica.059.02

X. Cifuentes-Mimoso T, Signes-Soler F. Estudio de efectos adversos tras tratamiento con implantes cutáneos de ácido hialurónico. Universitat Autonoma de Barcelona. Disponible en: https://semcc.com/master/files/Hialuronico%20y%20efectos%20adversos%20-%20Dras.%20Cifuentes%20y%20Signes.pdf.

XI. Robles M. Estudio de seguridad y eficacia del ácido hialurónico reticulado en relleno de surcos nasolabiales. doi: 10.47196/0573.

XII. Bogdan-Allemann I, Baumann L. Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging 2008;3(4):629-34. Doi: 10.2147/cia.s3118.

XIII. Jordan DR. Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthalmic Plast Reconstr Surg 2005 Sep;21(5):401-2. doi: 10.1097/01.iop.0000173194.18050.b8.

XIV. NASHATM. The monograpf. Disponible en: https://es.scribd.com/document/507252742/Monograph-ofNASHA.

XV. Cornejo P, Alcolea JM, Trelles MA. Perspectivas en el uso de materiales de relleno inyectables para tejidos blandos, desde nuestra experiencia. 1º parte. Cir Plast Iberolatinoam 2011;37(4):393-402. doi: 10.4321/S037678922011000400013.

XVI. Day D, Littler C, Swift R, Gottlieb S. The Wrinkle Severity
Scale. American Journal of Clinical Dermatology 2004;5:49-52. doi: 10.2165/00128071-200405010-00007.

XVII. Dibernardo G, DiBernardo B. Prediction of treatment outcomes for neck rejuvenation Utilizing a unique classification system of treatment approach using a 1440-nm side-firing laser. Aesthetic Surgery Journal 2018;38:S43-S51. doi:10.1093/asj/sjy066.
Ther 2022

XVIII. Sundaram H, Shamban A, Schlessinger J, Kaufman. Janette
J, Joseph, JH, Lupin M, Draelos Z, Carey W, Smith S, Eaton L. Efficacy
and safety of a new resilient hyaluronic acid filler in the correction
of moderateto-severe dynamic perioral rhytides. A 52-week prospective, multicenter, controlled, randomized, evaluator-blinded
study. Dermatol Surg. 2022 Jan 1;48(1):87-93. doi: 10.1097/DSS.0000000000003238.

XIX. Abduljabbar MH, Basendwh MA. Complications of hyaluronic acid fillers and their managements. Journal of Dermatology & Dermatologic Surgery 2016;20(2). doi: 10.1016/j.jdds.2016.01.001.

XX. Instrucciones de uso del producto Cientific Hyaluronic Facial Implant 30. Disponible en: https://es.scribd.com/document/265233528/Cientific-Hyaluronic-FacialImplant-30y18.

XXI. Kaufman-Janette J, Taylor SC, Cox SE, Weinkle SH, Smith S, Kinney BM. Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate-to-severe nasolabial folds. A 64-week, prospective, multicenter, controlled, randomized, doubleblind and within-subject study. J Cosmet Dermatol 2019 Oct;18(5):1244-1253. doi: 10.1111/jocd.13100.

XXII. Dayan S, Maas CS, Grimes PE, Beer K, Monheit G, Snow
S, Murphy DK, Lin V. Safety and effectiveness of VYC17.5L
for long-term correction of nasolabial folds. Aesthet Surg J 2020 Jun
15;40(7):767-777. doi: 10.1093/asj/sjz200.

Editor

Lugones Editorial

Fecha

31/03/2025

Colaborador

Allanmar International Company S.R.L

Identificador

DOI: https://doi.org/10.47196/0590

Citación

Marcelo Robles: Plastic and Reconstructive Surgeon, Medical Director, Robles Clinic, City of Buenos Aires, Argentina. ORCIDO: https://orcid.org/0009-0003-5622-8514 Claudio Dachevsky: Plastic Surgeon, General Manager, Lipo Plastic Surgery Clinic, São Paulo, Brazil, “Evaluation of the efficacy and safety of cross-linked hyaluronic acid
30 mg/ml for filling nasolabial folds,” Sello Editorial Lugones, consulta 2 de abril de 2025, https://ciencia.lugoneseditorial.com.ar/items/show/28.